Gov. Josh Shapiro joins lawsuit suing Trump Administration over gender-affirming care
More than 20 doctors and clinics that have been involved in transgender medical care were subpoenaed, and now Governor Shapiro is joining with 16 other Democratic officials suing the Trump Administration over restrictions for gender-affirming care for people under the age of 19.
The federal lawsuit filed in Boston alleges that attempts to deny medically necessary healthcare to transgender people through an executive order are unlawful.
According to the Department of Justice, however, these investigations include healthcare fraud, false statements, and more, saying those involved in performing these types of procedures on children will be held accountable.
The lawsuit claims the Trump Administration is targeting these individuals, as well as alleging the administration has intimidated healthcare providers. It says this order is unlawful because there is no federal statute that bans providing care to minors.
UPMC was among those subpoenaed along with others in Pennsylvania.
"These actions have made it abundantly clear that our clinicians can no longer provide certain types of gender-affirming care without risk of criminal prosecution," a UPMC spokesperson told KDKA-TV. "This includes specific restrictions on puberty blockers and hormone therapy for individuals under 19."
While it is unknown what will come from the lawsuit, UPMC has said they will continue to provide necessary healthcare within the bounds of the law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Who could run for Providence city councilwoman Helen Anthony's seat?
With Providence City Councilwoman Helen Anthony resigning in September to "more fully focus" on her health, there will now be a special election to fill her seat. Solve the daily Crossword
Yahoo
3 minutes ago
- Yahoo
This Beaten-Down 8%-Yielding Dividend Stock Is Finally on the Road to Recovery
Key Points Medical Properties Trust's new tenants are paying steadily rising rental rates. The company has a couple more catalysts ahead. It offers a high-yielding dividend and substantial upside potential as its stock price recovers. These 10 stocks could mint the next wave of millionaires › Medical Properties Trust (NYSE: MPW) has endured a rough couple of years. The hospital-focused real estate investment trust (REIT) has faced the bankruptcies of its two largest tenants. Their financial troubles occurred during a period when interest rates surged, making it challenging to refinance debt as it matured. Shop Top Mortgage Rates Your Path to Homeownership A quicker path to financial freedom Personalized rates in minutes However, the healthcare REIT has gotten past this rough patch. As a result, it's now finally on the road to recovery, which was evident in its second-quarter results. That puts its roughly 8%-yielding dividend on a much more sustainable foundation, making the REIT an interesting option for those seeking income and upside potential. New tenants are starting to contribute Medical Properties Trust spent much of last year dealing with the bankruptcy of its former top tenant, Steward Health Care. The REIT was able to take back control of its real estate from Steward last September as part of the bankruptcy settlement. That allowed the hospital owner to transition the hospital operations to new tenants. It ultimately replaced Steward with five new tenants at 17 properties. Those new tenants started paying rent this year under leases that steadily escalate rental rates over the next two years. The group collectively paid only $3.4 million in rent during the first quarter. That amount increased to $11 million in the second quarter as rental rates continued to escalate steadily. This represented 96% of the rent it billed to these tenants (it didn't collect $500,000 in rent from two facilities due to some start-up issues). Three of its tenants are already paying the fully ramped-up cash rate. Rising rental income from these tenants, along with continued stability from most of its existing portfolio, enabled Medical Properties Trust to book a total of $240.4 million of revenue during the quarter. Meanwhile, the REIT reported $0.14 per share of normalized funds from operations (FFO) in the period. That easily supported its dividend payment of $0.08 per share. The recovery should continue Medical Properties Trust anticipates that rents from its new tenants will increase to $17 million in the third quarter. This number should continue rising. The REIT expects to reach the fully stabilized rate in October 2026, of around $160 million annualized (approximately $40 million per quarter). That drives its confidence that its annualized cash rent will exceed $1 billion by the end of next year. "In summary, our transitional portfolio is quickly ramping performance and rent payments as expected, and our other tenants from around the world are delivering consistent performance, driven by healthy volume and cost trends," stated Rosa Hooper, senior VP of operations, on the second-quarter call. She continued, "Put simply, MPT's portfolio is well positioned to continue to generate significant cash flow and create value for shareholders moving forward." More potential catalysts ahead The company has several potential additional catalysts that could enhance its ability to grow shareholder value in the future. One is the final resolution with its other bankrupt tenant (Prospect Medical Holding). In March, the bankruptcy court approved a settlement between the REIT, Prospect, and other parties that will allow the bankrupt healthcare company to sell its hospital operations and the related real estate owned by Medical Properties Trust. As those sales occur, the REIT will receive funds that it can use to repay debt or invest in new income-generating assets. Medical Properties Trust also continues to explore ways to grow earnings, reduce its cost of capital, and enhance its valuation. For example, it continues to own very valuable hospital real estate that it could monetize, potentially through joint venture transactions. Future moves could help unlock shareholder value by selling stakes in its properties at strong valuations and recycling the capital into new, higher-return investments. These moves could boost its share price and its ability to rebuild its dividend. Healthy total return potential Shares of Medical Properties Trust currently sit more than 80% below where they were in early 2022 before interest rates started rising, and its tenant issues began to worsen. That slump is why the company offers such a high dividend yield despite two deep cuts. With its tenant and balance sheet issues now in the rearview mirror, the REIT's reset dividend is safe and could start rising in the future as its rental income increases. That growth, along with future moves to unlock shareholder value, could help drive a recovery in Medical Properties Trust's stock price. This combination of income and upside potential makes it a potentially very attractive investment opportunity these days. Trump's Tariffs Could Create $1.5 Trillion AI Gold Rush The Motley Fool's analysts are tracking a massive shift in U.S. tech. Over $1.5 trillion is already flowing into infrastructure, AI, and advanced manufacturing… and the number keeps climbing. Following a major tariff policy shift, a new AI Gold Rush is taking shape, and we think . It builds the tech infrastructure that Apple, OpenAI, and others suddenly can't live without. We just released a full write-up on this under-the-radar stock — and why now might be the exact moment to move. Continue » *Stock Advisor returns as of August 4, 2025 Matt DiLallo has positions in Medical Properties Trust. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This Beaten-Down 8%-Yielding Dividend Stock Is Finally on the Road to Recovery was originally published by The Motley Fool
Yahoo
3 minutes ago
- Yahoo
Pfizer raises annual profit forecast
(Reuters) -U.S. drugmaker Pfizer raised its full-year profit forecast on Tuesday, boosted by robust demand for its heart disease drug, Vyndaqel, and some older treatments. The drugmaker now expects to earn $2.90 to $3.10 per share on an adjusted basis in 2025, compared with its previous expectations of $2.80 to $3.00 per share. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
